• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Generalized Seizures - Pipeline Review, H2 2012 Product Image

Generalized Seizures - Pipeline Review, H2 2012

  • ID: 2335152
  • November 2012
  • 51 pages
  • Global Markets Direct

Generalized Seizures – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Generalized Seizures - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Generalized Seizures, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Generalized Seizures. Generalized Seizures - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Generalized Seizures.
- A review of the Generalized Seizures products under development by companies and universities/research READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Generalized Seizures Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Generalized Seizures 7
Generalized Seizures Therapeutics under Development by Companies 9
Generalized Seizures Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Generalized Seizures Therapeutics – Products under Development by Companies 14
Generalized Seizures Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Generalized Seizures Therapeutics Development 16
Eisai Co., Ltd. 16
Pfizer Inc. 17
UCB Group 18
Sihuan Pharmaceutical Holdings Group Ltd. 19
Generalized Seizures – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
lacosamide - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
perampanel - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
levetiracetam - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
diazepam - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
midazolam - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
levetiracetam - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Generalized Seizures Therapeutics – Drug Profile Updates 35
Generalized Seizures Therapeutics - Dormant Products 41
Generalized Seizures – Product Development Milestones 42
Featured News & Press Releases 42
Oct 04, 2012: Eisai Presents Phase III Data Supporting Europe's Newest Partial Epilepsy Treatment Fycompa At European Congress On Epileptology 42
Sep 24, 2012: UCB Sponsors Data Presentations On Epilepsy, Including New Data On Keppra At 10th European Congress On Epileptology 43
Sep 24, 2012: UCB Sponsors Data Presentations On Epilepsy, Including New Data On Keppra At 10th European Congress On Epileptology 44
Aug 22, 2012: Eisai Announces Publication Of Final Pivotal Phase III Fycompa Study Results In Epilepsia 44
Jul 27, 2012: European Commission Approves Eisai's AMPA Receptor Antagonist Fycompa 46
May 24, 2012: CHMP Adopts Positive Opinion For Variations In Marketing Authorization Of Eisai's Zonegran 46
Feb 06, 2012: Neurelis Announces FDA Allowance Of IND Application For NRL-1, Intranasal Diazepam Formulation 47
Jan 09, 2012: UCB Announces Positive Top-Line Results From Phase II Open-Label Pilot Study Of Vimpat In Primary Generalized Tonic-Clonic Seizures 48
Jul 18, 2011: Upsher-Smith Initiates Phase III Study Of Intranasal Midazolam For Rescue Treatment Of Seizure Clusters In Epilepsy Patients 48
Apr 14, 2011: Ortho-McNeil Neurologics Voluntarily Recalls Two Lots Of Topamax 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Number of Products Under Development for Generalized Seizures, H2 2012 7
Products under Development for Generalized Seizures – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Eisai Co., Ltd., H2 2012 16
Pfizer Inc., H2 2012 17
UCB Group, H2 2012 18
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Generalized Seizures Therapeutics – Drug Profile Updates 35
Generalized Seizures Therapeutics – Dormant Products 41

List of Figures
Number of Products under Development for Generalized Seizures, H2 2012 7
Products under Development for Generalized Seizures – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos